• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Corvex Inc. filed SEC Form 8-K: Other Events

    6/26/26 10:26:32 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email
    false 0001734750 0001734750 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 26, 2026

     

    CORVEX, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40254   82-4233771
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    3401 North Fairfax Drive, Suite 3230,

    Arlington, Virginia

      22226
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (866) GET-GPUS ((866) 438-4787)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   MOVE  

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    On June 26, 2026, Corvex, Inc. (the “Company”) commenced its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), as previously scheduled, and adjourned the Annual Meeting until July 1, 2026 at 3:00 pm, Eastern Time. Based on preliminary voting reports, all of the proposals on the agenda for the Annual Meeting have received overwhelming support from stockholders but the Company determined it was necessary to adjourn the meeting for certain administrative reasons.

     

    The close of business on April 28, 2026 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Annual Meeting. Stockholders may cast their votes by visiting http://www.proxyvote.com before the reconvened Annual Meeting or http://www.virtualshareholdermeeting.com/MOVE2026 during the reconvened Annual Meeting, or by calling 1-800-690-6903. Stockholders of the Company who have previously submitted their proxy or otherwise voted and who do not want to change their vote do not need to take any action. During the period of the adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals for the Annual Meeting

     

    The Company encourages all stockholders of record as of the close of business on April 28, 2026 who have not yet voted, to do so by June 30, 2026 at 11:59 pm Eastern Time. Notwithstanding the foregoing, any votes properly received before the close of the adjourned Annual Meeting on July 1, 2026 will be accepted.

     

    Additional Information and Where to Find It

     

    This document may be deemed to be solicitation material in respect of the Annual Meeting to be held on July 1, 2026. The Company previously filed a definitive proxy statement with the United States Securities and Exchange Commission (the “SEC”) on June 5, 2026. BEFORE MAKING ANY VOTING DECISIONS, SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ADJOURNED MEETING. The definitive proxy statement has been mailed to stockholders who are entitled to vote at the Annual Meeting. No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. The Company’s proxy statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at www.sec.gov.

     

    Participants in the Solicitation

     

    The Company and its directors and executive officers and other employees may be deemed to be participants in the solicitation of proxies in respect of the adjourned Annual Meeting.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CORVEX, INC.
         
    Date: June 26, 2026 By: /s/ Jay Crystal
        Jay Crystal
        Chief Executive Officer

     

    2

     

    Get the next $MOVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Demsey Seth converted options into 5,515,658 shares, increasing direct ownership by 178% to 8,563,155 units (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:31:37 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Co-Chief Executive Officer Crystal John Adler Iii converted options into 4,053,677 shares, increasing direct ownership by 109% to 6,414,723 units (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:31:04 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Fairbairn Emily converted options into 1,205,282 shares (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:30:26 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    SEC Filings

    View All

    SEC Form S-1 filed by Corvex Inc.

    S-1 - Corvex, Inc. (0001734750) (Filer)

    7/10/26 5:10:53 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Inc. filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Corvex, Inc. (0001734750) (Filer)

    7/7/26 5:10:57 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 filed by Corvex Inc.

    S-8 - Corvex, Inc. (0001734750) (Filer)

    7/1/26 4:58:37 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/12/24 4:30:19 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:08 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:14 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations

    Former Crusoe leader brings 25 years of experience across HPC architecture, GPU infrastructure, and site operationsARLINGTON, Va., July 15, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Michael Craig as Vice President of Architecture and Site Operations. Craig will lead cluster architecture and site operations for Corvex's AI Factory business, helping coordinate the technical, physical and supply-chain requirements necessary to convert high-density GPU infrastructure into reliable, prod

    7/15/26 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Stockholders Approve Key Governance and Capital Structure Proposals at 2026 Annual Meeting

    Company Disposes of Legacy Movano Assets; Shareholders Elect Three New Directors; Approve Conversion of Series C and Series D Preferred Stock; Chance Moreland Joins as CFOARLINGTON, Va., July 1, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the results of its 2026 Annual Meeting of Stockholders, held virtually. Shareholders voted to approve all proposals before them, including the election of three new directors to the Company's Board, authorization of the

    7/1/26 3:42:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Finance and AI Executive Patrick Fleury to Join Corvex Board of Directors as Company Scales AI Cloud Infrastructure Platform and Prepares to Launch Token Factory

    TeraWulf CFO brings deep expertise across data center transactions, energy-advantaged digital infrastructure campuses, and large-scale capital formationARLINGTON, Va., June 26, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Patrick A. Fleury to its Board of Directors, upon election at the Company's upcoming annual meeting. Fleury currently serves as Chief Financial Officer of TeraWulf Inc. (NASDAQ:WULF), a publicly traded developer, owner

    6/26/26 9:00:00 AM ET
    $MOVE
    $WULF
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    EDP Services
    Technology

    $MOVE
    Leadership Updates

    Live Leadership Updates

    View All

    Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations

    Former Crusoe leader brings 25 years of experience across HPC architecture, GPU infrastructure, and site operationsARLINGTON, Va., July 15, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Michael Craig as Vice President of Architecture and Site Operations. Craig will lead cluster architecture and site operations for Corvex's AI Factory business, helping coordinate the technical, physical and supply-chain requirements necessary to convert high-density GPU infrastructure into reliable, prod

    7/15/26 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Stockholders Approve Key Governance and Capital Structure Proposals at 2026 Annual Meeting

    Company Disposes of Legacy Movano Assets; Shareholders Elect Three New Directors; Approve Conversion of Series C and Series D Preferred Stock; Chance Moreland Joins as CFOARLINGTON, Va., July 1, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the results of its 2026 Annual Meeting of Stockholders, held virtually. Shareholders voted to approve all proposals before them, including the election of three new directors to the Company's Board, authorization of the

    7/1/26 3:42:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Finance and AI Executive Patrick Fleury to Join Corvex Board of Directors as Company Scales AI Cloud Infrastructure Platform and Prepares to Launch Token Factory

    TeraWulf CFO brings deep expertise across data center transactions, energy-advantaged digital infrastructure campuses, and large-scale capital formationARLINGTON, Va., June 26, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Patrick A. Fleury to its Board of Directors, upon election at the Company's upcoming annual meeting. Fleury currently serves as Chief Financial Officer of TeraWulf Inc. (NASDAQ:WULF), a publicly traded developer, owner

    6/26/26 9:00:00 AM ET
    $MOVE
    $WULF
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    EDP Services
    Technology

    $MOVE
    Financials

    Live finance-specific insights

    View All

    Corvex Reports Q1 2026 Financial Results and Provides Business Update

    Conference Call at 4:30 PM ET / 1:30 PM PTARLINGTON, Va., May 19, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, reported first quarter 2026 results and provided a business update. Reported Q1'26 Highlights:Completed acquisition of Corvex OpCo on March 19, 2026, transitioning the Company's primary business to AI cloud computing and renaming Movano Inc. to Corvex, Inc., effective March 23, 2026.Including 12 days of Corvex OpCo operations in the period, Q1'26 total revenue w

    5/19/26 4:06:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex to Host First Quarter 2026 Earnings Call on Tuesday, May 19, 2026

    Conference Call at 4:30 PM ET/ 1:30 PM PTARLINGTON, Va., May 11, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced that it will hold its first quarter 2026 earnings call on Tuesday, May 19, 2026 at 4:30 pm ET / 1:30 pm PT. Management will host a conference call and live audio webcast to discuss first quarter 2026 results and provide a business update. The live webcast of the earnings conference call can be accessed at the Corvex Investor Relations website at i

    5/11/26 8:30:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CORVEX, INC. ANNOUNCES ADDITIONAL DETAILS OF SPECIAL 35.8% STOCK DIVIDEND FOR SHAREHOLDERS OF RECORD ON MARCH 30, 2026

    ARLINGTON, Va., March 24, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE) ("Corvex" or the "Company") today announced additional details regarding the special 35.8% stock dividend (the "Stock Dividend") previously announced on March 19, 2026.  Each stockholder of record as of the close of business on March 30, 2026 will be entitled to receive a 35.8% stock dividend at no cost and with no action required on the part of the stockholder.For example, a stockholder holding 10,000 shares of Corvex common stock, par value $0.0001 per share (the "Common Stock") as of the close of tradin

    3/24/26 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    4/10/24 4:39:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Movano Inc. (Amendment)

    SC 13G/A - Movano Inc. (0001734750) (Subject)

    4/9/24 5:41:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    2/4/22 4:20:05 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care